Strides Pharma Science Ltd has announced the production of commercialized antiviral tablets for Favipiravir (259793-96-9) and stressed that the drug has been showing promising results in COVID-19 care globally. Favipiravir is an antiviral medicine initially developed in Japan for the treatment of influenza. Post the outbreak of Novel Coronavirus (COVID-19) in February 2020. Favipiravir was studied as a COVID-19 experimental treatment in China and several other countries.
"The drug has shown positive results, including a reduction in COVID-19 duration and improved lung conditions for the patients," the company said in a BSE filing. The product is a generic version of Toyama Chemical Avigan, Japan. Strides are the first Indian company to begin exporting Favipiravir tablets, the filing said. The company said it would apply immediately to Indian Drug Authorities to start necessary studies and make the drug quickly available to Indian patients. Strides produced 400 mg and 200 mg intensity Favipiravir tablets to provide easy dosage administration.
The drug is currently being exported to countries within the Gulf Cooperation Council (GCC) to treat patients under their COVID-19 treatment programmed. "Favipiravir tablets are being manufactured at Strides ' flagship facility in Bangalore, India. The facility can produce up to 6 billion solid oral units annually and is authorized by, among others, the USFDA, MHRA, WHO, TGA," it said.
Strides have also entered into a preferred arrangement for supplies of the Favipiravir API (active pharmaceutical ingredient) with a leading Indian API producer. In several trials on COVID-19 patients, Favipiravir has already shown positive results, and the company is hoping that the treatment regime with Favipiravir will stop the battle against this virus, he said.